“…Older adults, individuals with mild cognitive impairment (MCI) and preclinical individuals with positive AD biomarkers exhibit significant deficits in mnemonic discrimination of novel and studied targets under conditions of high feature overlap (Trelle et al ., n.d.; Yassa et al ., 2010, 2011; Ally et al ., 2013; Stark et al ., 2013; Reagh et al ., 2014; Stark and Stark, 2017; Berron et al ., 2018, 2019; Leal and Yassa, 2018; Gellersen et al ., 2020; Webb et al ., 2020). Similarly, cognitively healthy preclinical adults (defined by APOE genotype or AD pathologies), as well as MCI and AD patients, also perform significantly worse in tests of feature binding, showing a marked decline in representational fidelity (Atienza et al ., 2011; Rentz et al ., 2011; Troyer et al ., 2012; Della Sala et al ., 2012; Hampel, 2013; Bastin et al ., 2014; Oedekoven et al ., 2015; Parra et al ., 2015, 2019; Van Geldorp et al ., 2015; Koppara et al ., 2015; Mowrey et al ., 2016; Pietto et al ., 2016; Chen and Chang, 2016; Liang et al ., 2016; Polcher et al ., 2017; Zokaei et al ., 2019; Delhaye et al ., 2019; Konijnenberg et al ., 2019; Pavisic et al ., 2020; Valdés et al ., 2020; Korkki et al ., 2020).…”